/

Società

Je

Non verificato

Jeito Capital

Di cosa scriviamo

Annunci EconomiciFinanzaPubblicità/Marketing/Media/Comunicazione

11 comunicati stampa

Guarda tutti i comunicati

24/02/2026

Finanza

Annunci Economici

Pubblicità/Marketing/Media/Comunicazione

Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million

Fonte

Emittente

1.00

0

15/10/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital promotes Ksenija Pavletic to General Partner

Fonte

Emittente

1.00

0

10/09/2025

Finanza

Annunci Economici

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs

Fonte

Emittente

1.00

0

20/05/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health

Fonte

Emittente

1.00

0

12/05/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

Fonte

Emittente

1.00

0

11/05/2025

Finanza

Annunci Economici

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

Fonte

Emittente

1.00

0

23/03/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases

Fonte

Emittente

1.00

0

03/03/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients

Fonte

Emittente

1.00

0

07/01/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease

Fonte

Emittente

1.00

0

07/01/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0